JP2006525288A5 - - Google Patents

Download PDF

Info

Publication number
JP2006525288A5
JP2006525288A5 JP2006505607A JP2006505607A JP2006525288A5 JP 2006525288 A5 JP2006525288 A5 JP 2006525288A5 JP 2006505607 A JP2006505607 A JP 2006505607A JP 2006505607 A JP2006505607 A JP 2006505607A JP 2006525288 A5 JP2006525288 A5 JP 2006525288A5
Authority
JP
Japan
Prior art keywords
sequence
type
amino acid
information
length
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006505607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525288A (ja
Filing date
Publication date
Priority claimed from ES200301054A external-priority patent/ES2246105B1/es
Application filed filed Critical
Publication of JP2006525288A publication Critical patent/JP2006525288A/ja
Publication of JP2006525288A5 publication Critical patent/JP2006525288A5/ja
Pending legal-status Critical Current

Links

JP2006505607A 2003-05-08 2004-05-03 アルツハイマー病治療方法 Pending JP2006525288A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301054A ES2246105B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
PCT/ES2004/000194 WO2004098631A1 (es) 2003-05-08 2004-05-03 Método de tratamiento de la enfermedad de alzheimer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2011191515A Division JP2012006967A (ja) 2003-05-08 2011-09-02 アルツハイマー病治療方法
JP2014038360A Division JP2014129389A (ja) 2003-05-08 2014-02-28 アルツハイマー病治療方法

Publications (2)

Publication Number Publication Date
JP2006525288A JP2006525288A (ja) 2006-11-09
JP2006525288A5 true JP2006525288A5 (enExample) 2007-02-08

Family

ID=32982086

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006505607A Pending JP2006525288A (ja) 2003-05-08 2004-05-03 アルツハイマー病治療方法
JP2011191515A Pending JP2012006967A (ja) 2003-05-08 2011-09-02 アルツハイマー病治療方法
JP2014038360A Withdrawn JP2014129389A (ja) 2003-05-08 2014-02-28 アルツハイマー病治療方法
JP2016003772A Withdrawn JP2016065100A (ja) 2003-05-08 2016-01-12 アルツハイマー病治療方法
JP2018088643A Pending JP2018119011A (ja) 2003-05-08 2018-05-02 アルツハイマー病治療方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2011191515A Pending JP2012006967A (ja) 2003-05-08 2011-09-02 アルツハイマー病治療方法
JP2014038360A Withdrawn JP2014129389A (ja) 2003-05-08 2014-02-28 アルツハイマー病治療方法
JP2016003772A Withdrawn JP2016065100A (ja) 2003-05-08 2016-01-12 アルツハイマー病治療方法
JP2018088643A Pending JP2018119011A (ja) 2003-05-08 2018-05-02 アルツハイマー病治療方法

Country Status (19)

Country Link
US (6) US20090162362A1 (enExample)
EP (5) EP2356996B9 (enExample)
JP (5) JP2006525288A (enExample)
CN (2) CN101264326A (enExample)
AT (1) ATE435024T1 (enExample)
AU (2) AU2004237373A1 (enExample)
BR (1) BRPI0410684A (enExample)
CA (1) CA2524571C (enExample)
CY (1) CY1109454T1 (enExample)
DE (1) DE602004021797D1 (enExample)
DK (3) DK2356996T5 (enExample)
ES (6) ES2246177B1 (enExample)
IL (8) IL171651A (enExample)
MX (1) MXPA05010914A (enExample)
PL (3) PL2075007T3 (enExample)
PT (3) PT2356996E (enExample)
RU (2) RU2385161C2 (enExample)
SI (1) SI1623719T1 (enExample)
WO (1) WO2004098631A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2246177B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
JP5419131B2 (ja) * 2005-12-12 2014-02-19 エーシー イミューン ソシエテ アノニム 治療的特性を有するβ１〜４２特異的モノクローナル抗体
TWI551607B (zh) * 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
CA2701793C (en) * 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
RU2542967C2 (ru) * 2007-10-05 2015-02-27 Дженентек, Инк. Применение антитела против амилоида бета при глазных заболеваниях
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
EP2258398A1 (en) * 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
JP5745531B2 (ja) 2009-12-11 2015-07-08 アラクロン・ビオテック・エセ・エレ アミロイドベータペプチドの検出を改善するための方法および試薬
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
JP5934203B2 (ja) * 2010-07-14 2016-06-15 メルク・シャープ・エンド・ドーム・コーポレイション 抗ａｄｄｌモノクローナル抗体およびこの使用
CN103179981B (zh) * 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339014C (en) * 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
AU5525090A (en) * 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
JP2980677B2 (ja) 1990-04-27 1999-11-22 マクマイケル，ジョン 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
WO1994017197A1 (fr) * 1993-01-25 1994-08-04 Takeda Chemical Industries, Ltd. ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CA2340394A1 (en) * 1998-08-20 2000-03-02 Jorge R. Barrio Methods for labeling .beta.-amyloid plaques and neurofibrillary tangles
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
CA2500462A1 (en) * 2001-12-26 2004-03-25 Universidad De Zaragoza Polyclonal antibodies, preparation method thereof and use of same
EP1371986A1 (en) * 2002-06-06 2003-12-17 ABETA GmbH Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
ES2201929B1 (es) * 2002-09-12 2005-05-16 Araclon Biotech, S.L. Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
MXPA05003621A (es) * 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
PL378571A1 (pl) * 2003-02-01 2006-05-02 Neuralab Limited Czynna immunizacja dla wytworzenia przeciwciał przeciw rozpuszczalnemu A-ß
ES2246177B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.

Similar Documents

Publication Publication Date Title
JP2006525288A5 (enExample)
JP2012530145A5 (enExample)
DK1531791T3 (da) Forebyggelse og begrænsning af iskæmi
JPH0532696A (ja) 副甲状腺ホルモン誘導体
JP2014510518A5 (enExample)
NZ579566A (en) Modified fgf-21 polypeptides and their uses
RU2014131605A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
JP2004535461A5 (enExample)
EP2386566A3 (en) Chi-conotoxin peptides (II)
EA201100459A1 (ru) Композиции, включающие интерлейкин-1 и пептиды
WO2001027136A3 (fr) Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
TAKAGI et al. Amino acid sequence of troponin C obtained from ascidian (Halocynthia roretzi) body wall muscle
RU2007119376A (ru) Тимус - специфический белок
Bitar The primary structure of the ribosomal protein L29 from Escherichia coli
JP2021506815A5 (enExample)
Ilisz et al. High-performance liquid chromatography of biologically important, small epimeric peptides and their L, D-amino acid content
WO2001009174A3 (en) Plant defensin variants
JP2005501544A5 (enExample)
JP2003522184A5 (enExample)
JP2009503092A5 (enExample)
WO2024186679A2 (en) Rippled antiparallel cross-beta dimers and related materials, compositions and methods
WO2004064780A3 (en) Peptide-based angiogenesis inhibitors and methods of use thereof
JP2015506960A5 (enExample)
JP2002534996A5 (enExample)
ATE547424T1 (de) Chi-conotoxinpeptide mit einer n-terminalen pyroglutaminsäure